New Northwestern Memorial study demonstrates significant burden staph infections place on hospitals

August 08, 2005

Staphylococcus aureus infections (S. aureus) create an enormous burden to hospitals by significantly increasing costs, length of patient stays and mortality rates, a Northwestern Memorial Hospital researcher found in the most comprehensive study to date, published today's Archives of Internal Medicine. The study, led by Gary Noskin, MD, an infectious diseases specialist and medical director of healthcare epidemiology and quality at Northwestern Memorial, examined two years of data from hundreds of hospitals.

"S. aureus infections represent a considerable burden to U.S. hospitals, particularly among high-risk patient populations," said Dr. Noskin. "The potential benefits to hospitals in terms of reduced use of resources and costs, as well as improved outcomes from preventing S. aureus infections, are significant."

"There are currently a number of things being done to reduce the number of hospital-acquired S. aureus infections, including use of antibiotics to prevent surgical site infections, consistent hand-washing and maximum barrier protections when putting in central lines," adds Dr. Noskin. "There are also strategies to reduce S. aureus infections that are brought into the hospital such as performing a nasal swab to screen for S. aureus then attempting to eliminate it. Another important intervention is to make sure patients with certain infections are placed in isolation."

S. aureus infection was listed as a discharge diagnosis in nearly 1 percent of all hospital stays, or an average of 292,045 stays in a year, the study found. And S. aureus infection stays had, on average, 3 times the length of stay (14.3 vs. 4.5 days), three times the total charges ($48,824 vs. $14,141), and five times the risk of in-hospital death (11.2 percent vs. 2.3 percent) than stays without this infection. Even when controlling for patient differences in age, gender, race and comorbidities, the differences were significant: 9.1 days in excess length of stay, $32,856 in excess charges and 4 percent in-hospital mortality.

Applying these per stay estimates to the total number of S. aureus stays in the United States in a given year results in an estimated 2.7 million days in excess length of stay, $9.5 billion in excess charges, and close to 12,000 inpatient deaths per year. The differences remained significant when also comparing hospitalizations with S. aureus infections with other types of infections.

The study did not distinguish between infections that occurred before admission to the hospital or during a hospital stay. Also, the inability to measure "out of hospital" mortality, or mortality subsequent to the hospital stay, likely underestimates the impact of S. aureus infections on mortality.

S. aureus is a bacterium, frequently living on the skin or in the nose of a healthy person that can cause illnesses ranging from minor skin infections and abscesses, to life-threatening diseases. Long recognized as a frequent cause of healthcare-associated infections in acute care hospitals, it is often responsible for hospital-acquired pneumonia and surgical site infections, and is the second most common cause of bloodstream infections. An increasing percentage of S. aureus infections are caused by antibiotic resistant strains of the organism.

3M Healthcare was a study sponsor and financial support also came from a grant from the U.S. Public Health Service. According to Edwin Hedblom, health economic business manager from 3M Health Care, "no prior study has estimated the impact of S. aureus infections to this degree, in terms of clinical and financial outcomes that include length of stay (LOS), total charges, and in-hospital mortality, from nationally representative data."

Patient discharge data from 994 hospitals in 28 states in 2000 and 986 hospitals in 33 states in 2001 -- representing approximately 14 millions inpatient stays -- was analyzed to determine the association of S. aureus infections with length of stay, total charges and in-hospital mortality.

Other findings include:
-end-
About Northwestern Memorial Hospital

Northwestern Memorial Hospital is one of the country's premier academic medical centers and is the primary teaching hospital of Northwestern University's Feinberg School of Medicine. Northwestern Memorial and its Prentice Women's Hospital and Stone Institute of Psychiatry have 744 beds and more than 1,200 affiliated physicians and 5,000 employees. Providing state-of-the-art care, Northwestern Memorial is recognized for its outstanding clinical and surgical advancements in such areas as cardiothoracic and vascular care, gastroenterology, neurology and neurosurgery, oncology, organ and bone marrow transplantation, and women's health.

Northwestern Memorial received the prestigious 2005 National Quality Health Care Award and is listed in eight specialties in this year's U.S. News & World Report "America's Best Hospitals" issue. The hospital has also been cited as one of the "100 Best Companies for Working Mothers" by Working Mother magazine for the past 5 years and has been chosen by Chicagoans for a decade as their "most preferred hospital" in National Research Corporation's annual survey.

Northwestern Memorial HealthCare

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.